Results 71 to 80 of about 1,869 (168)

Lebrikizumab may benefit a subset of patients with asthma [PDF]

Thorax, 2011
Interleukin 13 (IL-13), a cytokine of type 2 helper T cells, may contribute to the heterogeneity of asthma in terms of clinical course and response to treatment. IL-13 leads to the production of periostin, a protein that may cause airway remodelling. In this randomised, double-blind, placebo-controlled study, lebrikizumab, a monoclonal antibody that ...
openaire   +1 more source

A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER) [PDF]

, 2020
BACKGROUND: The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab improves lung function in patients with moderate-to-severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown.
Sumino, Kaharu, et al.,, Austin, Cary D
core   +1 more source

Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis [PDF]

Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Moderate-to-severe AD severely affects patients’ quality of life. New drugs selectively targeting molecular pathways involved in the pathogenesis of the disease led to ...
Luca Stingeni, Cataldo Patruno, Amerio, Paolo, Caterina Foti, Paolo Amerio, Girolomoni, Giampiero, Silvia Ferrucci, Stingeni, Luca, Foti, Caterina, Giampiero Girolomoni, Ferrucci, Silvia, Patruno, Cataldo   +11 more
core   +1 more source

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

Journal of Dermatological Treatment
Aim of the study Lebrikizumab monotherapy demonstrated efficacy for adults and adolescents with moderate-to-severe atopic dermatitis (AD). This study aims to evaluate the relationship between lebrikizumab serum levels and stable deep response after ...
Jonathan I. Silverberg, Thomas Bieber, Kilian Eyerich, April W. Armstrong, Brian J. Nickoloff, Chitra R. Natalie, Gaia Gallo, Angela Okragly, Eric Wolf, Chenjia Xu, Brian A. Moser, Maria Jose Rueda, Hany Elmaraghy, Ozge Uluckan, Johann E. Gudjonsson   +14 more
doaj   +1 more source

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

, 2016
In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody, reduced exacerbation rates and improved FEV1 in patients with uncontrolled asthma, particularly in those with high concentrations of type 2 biomarkers (eg, periostin or blood ...
Eisner, Mark, PAGGIARO, PIER LUIGI, Sarah Gray, Kun Peng, Peng, Kun, Akihito Yokoyama, Matthews, John G., Chapman, Kenneth R, Bateman, Eric D, Asare, Charles, Kenneth R Chapman, Eric D Bateman, Wendy S Putnam, Charles Asare, Nicola A Hanania, Putnam, Wendy S, Mark Eisner, Hanania, Nicola A, Kopecky, Petr, Fischer, Saloumeh K, Holweg, Cecile T. J, Cecile T J Holweg, Petr Kopecky, Olsson, Julie, Pierluigi Paggiaro, Saloumeh K Fischer, Yokoyama, Akihito, Korenblat, Phillip, Gray, Sarah, Phillip Korenblat, Julie Olsson, John G Matthews   +31 more
core   +1 more source

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol

BMJ Open
Introduction Atopic dermatitis (AD) is a chronic, relapsing, heterogeneous skin disease affecting 2%–7% of adults, with roughly 30% having moderate-to-severe disease.
Matthias Augustin, Hilde Lapeere, Anthony Bewley, Christian Vestergaard, Thomas Werfel, Eric Massana, Ismail Kasujee, Marie-Charlotte Brüggen, Marjolein S de Bruin-Weller, Khaled Ezzedine, Silvia M Ferrucci, Spyridon Gkalpakiotis, Pedro Herranz, Emma K Johansson, Tomáš Kampe, Franz J Legat, Eva Maria Rehbinder, Jacek C Szepietowski, Tiago Torres, Arnau Domenech, Volker Koscielny, Siva Narayanan, Jan Gutermuth   +22 more
doaj   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice
Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be ...
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
doaj   +1 more source

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Journal of Dermatological Treatment
Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and ...
Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong   +8 more
doaj   +1 more source

Lebrikizumab. Anti-interleukin-13 monoclonal antibody Treatment of asthma

, 2014
Current advances in the knowledge of asthma pathobiology suggest that anti-cytokine therapies may be potentially useful for the treatment of this complex and heterogeneous airway disease. In particular, given the key role played by interleukin-13 (IL-13)
Rosario Maselli, Luca Gallelli, VATRELLA, Alessandro, Maria Teresa Busceti, Rosa Terracciano, Girolamo Pelaia   +5 more
core   +1 more source

Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Lebrikizumab is a novel monoclonal antibody that selectively binds to interleukin (IL)-13 with high affinity and a slow dissociation rate.
Emma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, Nathan Hahn, Brian J. Nickoloff, Christoph Preuss, Kimberly Siu, Chitra R. Natalie, Gaia Gallo, Eric Wolf, Kilian Eyerich, Mònica Aparici, Robert J. Benschop, Angela Okragly   +13 more
doaj   +1 more source